Sidewinder Therapeutics

Sidewinder Therapeutics is a clinical-stage biopharmaceutical company founded in 2023 and headquartered in San Diego, developing a new generation of precision bispecific antibody-drug conjugates (ADCs) for the treatment of solid tumors. Its engineered biologics bind two complexed targets simultaneously to increase tumor specificity, driving internalization of the antibody-receptor complex and its cytotoxic payload, with the goal of expanding the therapeutic window for hard-to-treat cancers such as colorectal, lung, and head-and-neck squamous cell carcinomas. The company raised an oversubscribed $137M Series B in 2026 (co-led by Frazier Life Sciences and Novartis Venture Fund, with DCVC Bio, OrbiMed, and others) and is advancing its bispecific ADC programs toward clinical development. Sidewinder is a biopharma research company and publishes no public developer or API surface.

Sidewinder Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Oncology, and Antibody-Drug Conjugates.

Sidewinder Therapeutics’ developer surface includes engineering blog, support, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyBiopharmaceuticalOncologyAntibody-Drug ConjugatesCancer TherapeuticsLife SciencesDrug Development

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 15.0/100 · emerging
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/sidewinder-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Sidewinder Therapeutics Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: sidewinder-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/sidewinder-therapeutics.png
name: Sidewinder Therapeutics
description: Sidewinder Therapeutics is a clinical-stage biopharmaceutical company founded in 2023 and headquartered in San
  Diego, developing a new generation of precision bispecific antibody-drug conjugates (ADCs) for the treatment of solid tumors.
  Its engineered biologics bind two complexed targets simultaneously to increase tumor specificity, driving internalization
  of the antibody-receptor complex and its cytotoxic payload, with the goal of expanding the therapeutic window for hard-to-treat
  cancers such as colorectal, lung, and head-and-neck squamous cell carcinomas. The company raised an oversubscribed $137M
  Series B in 2026 (co-led by Frazier Life Sciences and Novartis Venture Fund, with DCVC Bio, OrbiMed, and others) and is
  advancing its bispecific ADC programs toward clinical development. Sidewinder is a biopharma research company and publishes
  no public developer or API surface.
url: https://raw.githubusercontent.com/api-evangelist/sidewinder-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Oncology
- Antibody-Drug Conjugates
- Cancer Therapeutics
- Life Sciences
- Drug Development
apis: []
common:
- type: DomainSecurity
  url: security/sidewinder-therapeutics-domain-security.yml
- type: Website
  url: https://sidewinderbio.com/
- type: PrivacyPolicy
  url: https://sidewinderbio.com/privacy-notice
- type: TermsOfService
  url: https://sidewinderbio.com/terms-of-use
- type: Blog
  url: https://sidewinderbio.com/#news
- type: Support
  url: https://sidewinderbio.com/#contact
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io